Abbvie Inc.

Abbvic Inc.

Daniel E Cohen

Barry M Bernstein

Sandeep Dutta

Cheri E Klein

Walid M Awni

Sven Mensing

Thomas J Podsadecki

Rajeev M Menon

Scott C Brun

Emily O Dumas

Amit Khatri

Tami J Pilot-Matias

Christine Ann Collins

Preethi Krishnan

Gennadiy Koev

Isabelle A Gaultier

Rakesh L Tripathi

This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

Compositions and methods for treating HCV

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Methods for treating HCV

The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Growing community of inventors

Wilmette, IL, United States of America

Daniel E Cohen